Headless WordPress - PROD

Individualizing LAI selection based on clinical profile, tolerability, and real-world feasibility

https://sharecareprofessional.top/hcp/neurology/long-acting-injectables-schizophrenia-formulation

Long-acting injectables (LAIs) in schizophrenia: Matching formulation to patient need

Growing evidence supports earlier consideration of injectable therapy

https://sharecareprofessional.top/hcp/neurology/timing-long-acting-injectable-initiation-schizophrenia

Rethinking the timing of long-acting injectable initiation in schizophrenia management

Systemic, educational, and patient-level factors shape access and implementation across care settings

https://sharecareprofessional.top/hcp/neurology/barriers-lai-adoption-community-psychiatric-care

Addressing real-world barriers to LAI adoption in community psychiatric practice

Digital tools, AI-driven monitoring, and integrated care models represent the next frontier in management

https://sharecareprofessional.top/hcp/neurology/emerging-technologies-schizophrenia-care-future

Emerging technologies and the evolving future of schizophrenia care

Featured Content

https://screening.mhanational.org/screening-tools/psychosis/

Screening Tools: Psychosis & Schizophrenia Test

https://mhanational.org/conditions/schizophrenia/

https://mhanational.org/resources/life-psychosis/

Learn what it's like to live with Psychosis

Partner Resources

Dx Dialogues: Schizophrenia

Dr. Ragy Girgis, MD, MS, Professor of Clinical Psychiatry at Columbia University and the New York State Psychiatric Institute, discusses LAI candidacy, stigma and patient education, and the latest pharmacologic advances in schizophrenia treatment.